30% of synthesized molecules have measured activity which meet potency targets.
NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus®
Simulations Plus announced that China's Center for Drug Evaluation of the NMPA has added GastroPlus licenses for research aiding regulatory reviews
Simulations Plus Celebrates 25 Years in Business
Continuing the commitment to improve public health through innovative solutions
Simulations Plus Sets Date for Third Quarter Fiscal Year 2021 Earnings Release and Conference Call
Conference call to be on Monday, July 12, 2021, at 4:15 p.m. ET
Simulations Plus Releases IPFsym version 1A, State-of-the-Art Quantitative Systems Pharmacology (QSP) Software for Idiopathic Pulmonary Fibrosis (IPF)
IPFsym will enable new software and services revenue by aiding development of IPF therapies
Simulations Plus to Participate in 18th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus to Participate in 18th Annual Craig-Hallum Institutional Investor Conference
Simulations Plus Uplisted to The Nasdaq Global Select Market®
Strong growth, innovation, and global reach drive the company’s progress
Simulations Plus Releases ADMET Predictor® (X.2)
Industry-driven enhancements further establish ADMET Predictor® as the preferred platform for discovery PBPK simulations
U.S. FDA Renews Licenses of DILIsym Software
FDA Renewal Allows for Evaluation of DILIsym Submissions by Sponsors
Simulations Plus Reports Record Second Quarter Fiscal 2021 Financial Results
Second quarter revenue of $13.1 million, reflecting 27% year-over-year growth
Board of Directors announces quarterly dividend of $0.06 per share
Simulations Plus Reports Successful Results from AIDD Collaboration with Large Pharmaceutical Company
80% of preliminary molecules tested exhibit submicromolar activity and acceptable ADME properties
Simulations Plus Sets Date for Second Quarter Fiscal Year 2021 Earnings Release and Conference Call
Conference call to be on Monday, April 12, 2021, at 4:15 p.m. ET
Simulations Plus Forms Scientific Advisory Board for RENAsym Consortium
RENAsym SAB to Provide Insights and Guidance for Development of Kidney Injury Software
Simulations Plus Hosts the Inaugural 2021 MIDD+ Scientific Conference with over 50 Model-Informed Drug Development Sessions
Speakers from Academia, Large Pharma Collaborations and Regulatory Agencies shared their real-world impact using modeling & simulation technology
Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration
Computational Modeling, Human Liver Microphysiology Systems (MPS) and the MPS-Database Platforms to be Integrated for Safety Testing
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Simulations Plus Releases GastroPlus® Version 9.8.1
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and...
Simulations Plus Enters Agreement with Distributor in China
Extends reach of MonolixSuite™ to China’s growing pharmacology market
Simulations Plus Expands Marketing and Sales Operations in South America Through Partnership with the Institute of Pharmaceutical Sciences
New distribution channel will accelerate adoption of software and services in emerging markets